Authors and Disclosures
William J. Elliott, MD, PhD, Professor of Preventive Medicine, Internal Medicine, and Pharmacology, Rush Medical College, Chicago, Illinois; Joseph L. Izzo, Jr, MD, Professor of Medicine and Vice Chair of Medical Research, Department of Medicine, State University of Buffalo, Buffalo, New York
Disclosure: William J. Elliott, MD, PhD, reports no employment other than at Rush Medical College since 1992, no stock ownership, no options, and he has never received any remuneration or other support for expert testimony. He reports having served as principal investigator for a clinical trial evaluating the use of the RESPeRATE device in 2002, for which Rush Medical College (his employer) received monies under a contract to perform the clinical trial. Dr. Elliott has been an inventor on one patent (use of a synthesized chemical to control Dutch elm disease) but holds or has pending no patents related to human medicine. Dr. Elliott has received royalties from Elsevier for a forthcoming monograph about hypertension that does not mention or discuss the RESPeRATE device or other modalities to lower blood pressure through slow breathing. Dr. Elliott has disclosed that he has received grants and/or research support from Pharmaceutical Manufacturers' Association Foundation, Smith, Kline & French Laboratories, Hoechst Marion Roussel, Inc., Glaxo, Inc., SmithKline Beecham, Inc., G. D. Searle & Co., Boehringer Ingelheim, Inc., National Institutes of Health, American Heart Association -- Chicago, Abbott Laboratories, Pfizer Inc., Bristol-Myers Squibb, Inc., Knoll Pharmaceuticals, Merck Human Health, Sankyo Pharmaceuticals, Wyeth-Ayerst, Inc., Astra Merck, Inc., Novartis Pharmaceuticals Corporation, Omron Healthcare, AstraZeneca, LP, and Mylan Laboratories. Dr. Elliott has disclosed that he has served as a consultant to Smith, Kline & French Laboratories, National Heart, Lung, and Blood Institute, G.D. Searle & Co., Curative Technologies, Inc., Agency for Health Care Policy & Research, Bristol-Myers Squibb, Inc., Pfizer Inc., AstraZeneca, LP, Biovail Pharmaceuticals, Inc., and Kos Pharmaceuticals, Inc. Dr. Elliott has disclosed that he has volunteered for the local speaker's bureau for the American Heart Association and has given occasional lectures supported by Abbott, Astra Merck, Astra Pharmaceuticals, LP, Astra, USA, AstraZeneca, Bayer Pharmaceuticals Co., Biovail Pharmaceuticals, Inc., Bristol-Myers Squibb, Ciba-Geigy, Inc., CibaGeneva Pharmaceuticals, Inc., E. R. Squibb & Sons, G.D. Searle & Co., Glaxo, Inc., Hoechst-Marion-Roussel, ICI Pharma, Key Pharmaceuticals, Knoll Pharmaceuticals, Kos Pharmaceuticals, Marion Merrell-Dow, Merck Human Health, Merck, Sharp & Dohme, Monsanto, Neurex, Inc., Novartis Pharmaceuticals Corp., Parke-Davis, Inc., Pharmacia, Pfizer Inc., Procter & Gamble, Sandoz, Inc., Schwarz Pharmaceuticals, Syntex, Inc., Solvay Pharmaceuticals, Inc., The Upjohn Company, Unimed Pharmaceuticals, Wyeth-Ayerst, Inc., and Zeneca, Inc. Dr. Elliott has also disclosed unspecified financial or material support from Lederle Laboratories, Forest Pharmaceuticals, Eli Lilly, and Rhône-Poulenc Rorer.
Disclosure: Joseph L. Izzo, Jr, MD, has disclosed that he has been granted a limited number of stock options in InterCure and has conducted one clinical trial with the device. Dr. Izzo has also disclosed that he serves on the scientific advisory board of InterCure. Dr. Izzo has also disclosed that he is the editor for the Hypertension Primer and has coauthored a chapter ("Respiration and Blood Pressure") in the third edition that does not mention the RESPeRATE device manufactured by InterCure.
Comments